Zealand Pharma A/S (OTCMKTS:ZLDPF) Posts Quarterly Earnings Results, Beats Expectations By $1.45 EPS

Zealand Pharma A/S (OTCMKTS:ZLDPF) released its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.57) by $1.45, Zacks reports. Zealand Pharma A/S had a net margin of 58.86% and a return on equity of 17.56%.

Zealand Pharma A/S Stock Down 3.7%

OTCMKTS ZLDPF traded down $1.35 on Thursday, reaching $35.50. 515 shares of the stock traded hands, compared to its average volume of 2,350. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. The company has a fifty day moving average price of $38.85 and a 200-day moving average price of $46.81. The company has a market cap of $2.54 billion, a price-to-earnings ratio of 5.89 and a beta of 0.99. Zealand Pharma A/S has a 12 month low of $33.08 and a 12 month high of $83.12.

Analyst Upgrades and Downgrades

ZLDPF has been the topic of a number of recent analyst reports. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Zacks Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.